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Invasive lobular carcinoma accounts for 5%–15% of all invasive breast cancers, with a
marked increase in incidence rates over the past two decades. Distinctive biological
hallmarks of invasive lobular carcinoma include the loss of cell adhesion molecule E-
cadherin leading to cells with a discohesive morphology, proliferating into single-file
strands and estrogen receptor positivity. These key molecular features can make
diagnosis difficult, as invasive lobular carcinoma is challenging to detect both physically
and with current standard imaging. Treatment of invasive lobular carcinoma strongly
favors endocrine therapy due to low chemosensitivity and lower rates of pathological
response as a result. This review will summarize the distinct biological and molecular
features of invasive lobular carcinoma, focusing on the diagnostic challenges faced and
the subsequent surgical and medical management strategies. Prospective therapeutic
options will also be explored, highlighting how furthering our understanding of the unique
biology of lobular breast carcinoma is essential in guiding and informing the treatment of
patients in the future.
Keywords: treatment, imaging, diagnosis, molecular features, lobular breast cancerINTRODUCTION
Invasive lobular carcinoma (ILC) accounts for 5%–15% of all invasive breast cancers (BCs) and is
the second most common type of BC behind invasive ductal carcinoma (IDC) of no special type (1).
Over the last two decades, there has been a marked increase in the incidence of ILC, mainly among
the post-menopausal population. This is likely the result of improved diagnostic techniques and the
use of hormone replacement therapy (2). ILC has a distinct biological profile and thus presents
unique challenges with regard to systemic treatment and management of the disease. Hallmark
features of ILC include; the loss of cell-cell adhesion molecule E-cadherin, resulting in small,
discohesive cells proliferating in single-file strands, positivity for both the estrogen (ER) and
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) negativity (3).
These key pathological features alongside the diffuse growth pattern of ILC make establishing a
diagnosis particularly challenging. ILC is difficult to detect both upon physical examination and
with standard imaging techniques. However magnetic resonance imaging (MRI) has a reported
greater sensitivity in the detection and characterization of ILC than “gold standard”mammography.
Systemic therapy is an integral part of the multidisciplinary approach to treating BC and this often
involves the use of chemotherapy. However, due to the unique molecular biology of ILC, treatment
response to chemotherapy is often predictably poor, resulting in lower rates of completeJanuary 2021 | Volume 10 | Article 5913991
Wilson et al. Lobular Breast Cancerpathological response (pCR) thus leading to an increase in
mastectomy rates in these patients (4). On the other hand,
studies have shown that ILC responds well to endocrine
therapy (ET), making it the optimal choice in the treatment of
ILC (3, 5). The use of letrozole seems to provide greater overall
survival (OS) benefit compared with tamoxifen, suggesting an
increased incidence of endocrine resistance in ILC patients
treated with tamoxifen (6). A deeper understanding of the
unique molecular profile and alterations that define this BC
subtype will lead the way in improving diagnosis, management,
and treatment outcomes for patients with ILC. This review
provides an up-to-date summary of the current understanding
of ILC by discussing diagnostic challenges, surgical and medical
management strategies, and prospective directions in the
treatment of ILC.INCIDENCE
ILC accounts for 5%–15% of all reported cases of BC (1, 7). On
average, patients are 3 years older at diagnosis in comparison to
IDC and are generally diagnosed at a more advanced stage of
disease. Thus, tumors are often larger and show a greater degree
of lymph node involvement at clinical presentation (7). The
incidence of ILC has also increased over the past two decades,
particularly in women over the age of 50 and is likely a result of
diagnostic advances. It has also been correlated with the use of
hormone replacement therapies, particularly those containing
progesterone (8, 9). Several studies have suggested that the use of
combined hormonal replacement therapy is related to a higher
relative risk of BC (10–12). Since ILC is strongly ER-positive, it is
unsurprising that prolonged and increased exposure to
hormones represents a risk factor. Traditional hormone-related
risk factors, including earlier menarche, later menopause, low
parity, and late age at first birth, are all associated with increased
incidence of ILC.
It has also been suggested that some lifestyle factors like
alcohol consumption may play a role in ILC and IDC incidence.
Among the first studies or even perhaps the first one that
reported alcohol intake was positively related to ductal
and lobular tumors was the study by Van’t Veer et al. (13).
They showed that consuming more than 30 g of alcohol per day
may enhance the BC risk in premenopausal women and that anFrontiers in Oncology | www.frontiersin.org 2early start to drinking alcohol may increase the relative risk for
BC even beyond menopause (13). A great number of studies
followed investigating the risk of alcohol intake and BC.
ILC is more frequent in the Western world while its incidence
is much lower in the Middle East, Africa and Asia, accounting for
only around 5% of BC cases in these regions. This is likely due to
genetic factors (7). Hereditary ILC is rare but cases have been
reported to occur as a secondary tumor in patients or families
with hereditary diffuse gastric cancer syndrome who harbor a
germline mutation of the CDH1 gene (14). The risk factors of
ILC are summarized in Table 1.MORPHOLOGICAL FEATURES AND
IMMUNOPHENOTYPE OF ILC
ILC often displays favorable characteristics that are associated
with a good prognosis, typically being strongly ER positive and of
a lower histological grade. As many as 95% of ILC cases express
the ER and up to 70% of cases express the PR (15–18). By
comparison only 60%–70% of IDC express both ER and PR.
Figure 1 shows the differences in morphological features
between ILC and IDC. ILC can demonstrate a number of
histological variants, these include classic, solid, alveolar,
mixed, tubulo-lobular, and pleomorphic lobular carcinoma (1).
Small, round, discohesive cells that are often described as having
signet-ring cell morphology define the classic subtype. The
distinct growth pattern features cells growing in linear strands
through the stroma, with little disturbance to the surrounding
breast tissue architecture (Figure 2). This arrangement of cells
also forms in concentric patterns around structures such as ducts
and lobular units (17). In addition, classical ILC is associated
with low to moderate nuclear pleomorphism and a low mitotic
index (1). The low proliferative index demonstrated by the
majority of ILC may contribute to the lack of chemo-
responsiveness. Histological variants of ILC can be identified
either by their growth patterns or their cytology. The histology of
the solid variant of ILC differs from classic type by forming large
solid sheets of neoplastic cells, that can potentially be mistaken
for other tumors such as lymphoma. This variant is commonly
associated with high nuclear pleomorphism and a higher mitotic
index (16). The alveolar variant is cytologically similar to classic
ILC but cells tend to grow in groups of at least 20 cells, forming
globular aggregates (17). The presence of tubular structures in
association with the distinct filing growth pattern defines the
tubulo-lobular variant of ILC (16). Pleomorphic lobular
carcinoma was first described in 1982 by Dixon et al. and is
characterized by a greater degree of nuclear atypia and
pleomorphism and a higher mitotic index, conferring a more
aggressive phenotype than classic ILC (18). The pleomorphic
variant does retain the classic ILC pattern of single cell files, even
if the architecture of the lesion is often mixed (Figure 3). This
aggressive phenotype is often associated with a poorer prognosis
when compared to other ILC variants (19). Weidner et al. (20)
reported that patients with pleomorphic ILC were four times
more likely to experience recurrence than patients affected byTABLE 1 | A summary of the primary risk factors associated with the
development of invasive lobular breast cancer.
Risk factors associated with Invasive Lobular Breast Cancer
• Alcohol consumption
• Use of combined hormone replacement therapy
• Early menarche (defined as menarche before the age of 12 years)
• Late-onset menopause (defined as menopause after the age of 55 years)
• Nullparity/low parity (defined by WHO as less than 5 pregnancies with
gestation periods of ≥20 weeks)
• Late age at birth (>30 years)
• Family history, e.g., hereditary diffuse gastric cancer syndrome
• Genetics, e.g., CDH1 mutationsJanuary 2021 | Volume 10 | Article 591399
Wilson et al. Lobular Breast CancerFIGURE 1 | Comparison of invasive lobular carcinoma and invasive ductal carcinoma of no special type. (A, B) Haematoxylin and Eosin stained sections
demonstrating the morphology of ILC and IDC of no special type. (A) ILC showing diffuse infiltration of the stroma with a single file pattern, surrounding a normal
breast duct in a concentric manner. (B) IDC showing more cohesive tumor cells forming tubules with destructive infiltration of the mammary stroma. (C, D)
Comparison of E Cadherin expression in ILC and IDC of no special type. (C) Complete absence of staining is seen in ILC. (D) Strong and diffuse membranous
expression is seen in IDC.FIGURE 2 | Classical morphology and immunophenotype of invasive lobular carcinoma. (A–C) Haematoxylin and Eosin stained sections demonstrating the classical
morphology of invasive lobular carcinoma (ILC). (A) Single file pattern of invasion, highlighted with bracket ({}. (B) High power view showing discohesive tumor cells.
An intracytoplasmic vacuole is highlighted with the red arrow. (C) Concentric pattern of infiltration around a normal breast duct, highlighted with asterisk (*). (D–F)
Classical immunophenotype of ILC. Strong and diffuse nuclear expression of (D) oestrogen receptor and (E) progesterone receptor. (F) Absence of membranous E
Cadherin expression.Frontiers in Oncology | www.frontiersin.org January 2021 | Volume 10 | Article 5913993
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530 cases of ILC (57% classic, 19% alveolar, 11% solid, and 13%
displayed pleomorphic or apocrine features). In this study,
classic histology was associated with a lower risk of lymph
node metastasis and a lower tumor grade compared to non-
classic histology, which showed an increased number of distant
metastases and a significant reduction in disease-free survival
(DFS) and OS. Talman et al. (22) evaluated 860 tumors of
patients with classic or non-classic ILC, regarding subtype and
grade in relation to prognosis. The results showed that most
cases of classic ILC were grade II tumors, with a small portion
being grade I but prognosis remained the same despite this.
There was a higher frequency of grade III tumors among solid
and pleomorphic subtypes and this was associated with a
significantly worse survival outcomes compared to grade II
tumors. A study by Iorfida et al. (23) featuring 981 ILC
patients, reported a longer DFS and BC-specific survival
(BCSS) in those with classic ILC rather than patients with solid
and mixed variants. Despite the overall good prognosis
associated with classic ILC, tubulo-lobular variants may exhibit
the best prognosis of all ILC subtypes. Noteworthy, du Toit et al.
(24) investigated 171 cases of ILC over a period of 11 years
reporting a 12-year survival rate of 100% for tubulo-lobular
subtype. This excellent prognosis is reflected in the fact thatFrontiers in Oncology | www.frontiersin.org 4tubulo-lobular tumors are likely to be of low histological grade
and are often node negative. In contrast, patients with
pleomorphic ILC generally have a poorer prognosis, presenting
at an advanced stage of disease with larger tumors and
lymphovascular invasion (25). Biomarkers associated with poor
clinical outcomes are rarely displayed in ILC; however,
pleomorphic ILC is an exception to this rule, exhibiting a lack
of ER and PR expression, HER2 amplification, p53 expression
and higher proliferation rates (16).MOLECULAR FEATURES OF ILC
The characteristic feature of ILC is the loss or lack of E-cadherin
expression (26). E-cadherin is an essential molecule in mediating
cell-cell adhesion in order to maintain cell viability;
dysregulation results in the distinctive discohesive growth
pattern observed in ILC. E-cadherin is able to from adherens
junctions between cells through association with a-, b-, g-, and
p120 catenins, together they work to maintain cellular cohesion.
Approximately, 90% of ILCs lack E-cadherin expression, a
feature that is important in the diagnosis and classification of
ILC, particularly when differentiating from IDC. In addition to
the loss of E-cadherin, a-, b-, g-catenins are also lost in ILC butFIGURE 3 | Morphological variants of invasive lobular carcinoma. (A–D) Haematoxylin and Eosin stained sections showing morphological variants of ILC. (A) Solid
growth pattern. (B) Signet ring morphology with prominent intracytoplasmic mucin vacuoles, highlighted with red arrows. (C) Pleomorphic ILC showing more
prominent nuclear atypia with conspicuous nucleoli (red arrow) and mitotic activity (blue arrow). (D) Tubulolobular carcinoma showing tubule formation (blue arrows)
alongside the classical single file pattern of invasion (red arrows).January 2021 | Volume 10 | Article 591399
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acting as another biomarker of ILC (16). The hallmark loss of E-
cadherin is driven by alterations to the CDH1 gene, located on
chromosome 16q22, which codes for E-cadherin. Despite the
strong association between CDH1 mutation or deletion and the
hallmark loss of E-cadherin in ILC, mechanisms underlying this
alteration are not well studied (27). The most likely explanation
for the inactivation of CDH1 follows the “two-hit hypothesis”
model where a first-event somatic mutation is followed by loss of
heterozygosity or gene methylation. Mutations in CDH1 have
been identified in other epithelial cancers, most notably in diffuse
gastric cancer, which shares similar features with ILC (28).
Namely, the appearance of neoplastic and signet ring cells in
an infiltrative growth pattern (16). The International Gastric
Cancer Linkage Consortium studied 11 CDH1 families and
interestingly found that in addition to diffuse gastric cancer,
female gene carriers were also at a higher risk of developing ILC
(14). Overall, this suggests CDH1 inactivation is a key event in
the pathogenesis of ILC (29). CDH1 is not the only genomic
alteration associated with ILC.
The Cancer Genome Atlas (TCGA) study has also identified a
number of ILC-enriched mutations including FOXA1, RUNX1,
and TBX3 (5). FOXA1 expression is high in BC and mutations
are present in approximately 7% of all ILC cases (30). FOXA1 is
as a key transcription modulator of ER activity, thereforeFrontiers in Oncology | www.frontiersin.org 5mutations can affect ER function as the loss of ER-binding
blocks ER-mediated gene expression, altering the response of
endocrine targeted therapies such as Tamoxifen (3). In a study
conducted by Desmedt et al. (31), aimed to characterize
the genome of 630 ILC tumors, CDH1 mutations occurred in
65% of tumors. However, the phosphatidylinositol 3-kinase
(PI3K) pathway showed three key genes with alterations:
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit alpha (PIK3CA), phosphatase and tensin homolog
(PTEN) and AKT1 mutations were present in 50% of cases.
PIK3CA mutations were associated with low proliferation rates,
as defined by Ki-67 and AKT1 tumors were related to a short-
term risk of relapse. While loss or inactivation of PTEN can
result in a more aggressive phenotype (Figure 4) (3).
ILC is overwhelmingly characterized by HER2 negativity,
displaying a low rate of ERBB2 amplification. However, ERBB2
mutations or amplifications have been found in up to 8% of ILCs.
These mutations are most associated with pleomorphic and solid
histology and this is thought to account for the aggressive tumor
phenotype (31, 32). Outside of mutations in CDH1 and members
of the PI3K pathway, few other potential driver mutations in ILC
have been identified. ILC harbors fewer chromosomal alterations
than IDC, typically exhibiting a high frequency of gain of
chromosome 1q and loss of 16q (33, 34). Gene expression
profiling studies have categorized BC into four “intrinsicFIGURE 4 | Molecular, pathology, and immunophenotype features of ILC.January 2021 | Volume 10 | Article 591399
Wilson et al. Lobular Breast Cancersubtypes”—luminal A, luminal B, Her 2 enriched and basal like
(35). ILC are frequently classified as luminal A, in keeping with
the majority of tumors being low grade and ER positive.
However, significant heterogeneity exists and ILC have the
potential to be classified as any of the four main intrinsic
subtypes (36). A better understanding of the molecular and
genomic alterations that characterize ILC will facilitate a more
personalized approach to treating BC.DIAGNOSIS OF LOBULAR CANCER
Diagnosis of ILC by physical exam can be challenging as patients
often present with limited clinical signs and do not always have a
palpable breast lump; signs may be frequently vague such as skin
thickening or dimpling. Measuring the extent of ILC can be
difficult as traditional screening methods such as mammography
and ultrasound (US) have a low sensitivity for detecting ILC
compared to other invasive breast tumors. This difficulty can be
largely attributed to the diffuse infiltrative growth pattern of
ILC (2).
Mammography
Mammography is considered the “gold standard” imaging
method in the early detection of BC (1) with a sensitivity
typically ranging from 63% to 98%. This is achieved by
producing high-resolution images, highlighting the contrast
differences between healthy and malignant breast tissue (37).
Detection of ILC using mammography is notoriously challenging
due to the infiltrative tumor growth pattern which does not
destroy the underlying anatomic structures or incite a
desmoplastic stromal reaction. Due to these uncommon tumor
characteristics, the sensitivity in detecting ILC is much lower,
ranging between 57% and 81%. False positives are also not
uncommon with reported rates ranging from 8% to 24% (2). A
study by Krecke and Gisvold reported that the false-negative rate
in the diagnosis of ILC is much higher than that for other
invasive BCs (38). Furthermore 54% of mammograms that were
deemed to show no evidence of malignancy were later found to
be suggestive of a tumor. Upon reviewing these mammograms,
46% still concluded no visual evidence of malignancy. The
inverse relationship between breast tissue density and
mammographic sensitivity is well established. In the case of
extremely dense breast tissue, mammographic detection can be
as low as 30% (37). In a study by Berg et al. (39) mammographic
sensitivity was found to be around 34% in cases of ILC and when
adjusting for patients with dense breast tissue sensitivity
decreased to just 11%. In addition to its distinct histological
growth pattern, low opacity may also explain the challenges of
clinically identifying ILC with mammography (40). A study by
Hilleren et al. (41) reported that up to 50% of ILC have a lack of
opacity which is less than or equal to normal breast tissue upon
imaging. This lack of contrast highlights the challenge in
delineating between malignant and normal breast tissue using
conventional mammography in ILC (37). Invasive carcinomas
are often associated with high density spiculated masses, due to
the disruption of normal breast tissue architecture. This kind ofFrontiers in Oncology | www.frontiersin.org 6mass can be easily detected by mammography. Reports suggest
that ILC manifest as a poorly spiculated and ill-defined lesions,
with a well-defined mass seen in less than 1% of cases (37). In
addition, up to 35%, of ILCs are reportedly only visible on one
view, this is most often the craniocaudal view (2). This may also
contribute to estimations of tumor size and extent being less
reliable (42). Microcalcifications are often considered common
indicators of breast disease and are readily detected by
mammography, however the likelihood of ILC producing
calcifications is low (43). The presence of calcifications
associated with ILC reportedly ranges from 1% to 28%. This is
another hallmark feature of ILC that contributes to the inability
of mammography to readily detect these tumors. Given all of the
above it is unsurprising that the threshold for recommending
additional imaging methods remains low (37).
Ultrasound
US is another diagnostic breast imaging tool that is most
commonly used in conjunction with mammography. US was
originally used as a tool to differentiate between solid and cystic
lesions and to guide biopsy procedures (44). However, with
technological advances, US now has improved sensitivity to
separate benign from malignant lesions and is used in the
investigation of all palpable breast lumps (37). The relationship
between breast density and mammography sensitivity is well
documented however with the addition of US, there may be up
to a 40% increase in the detection of asymptomatic cancers,
which often include ILC (40). The reported sensitivity of US
in the detection of ILC ranges from 68% to 98% (37, 45). The
most common sonographic features of ILC are an irregular,
hypoechoic mass with ill-defined margins and posterior
shadowing, observed in up to 61% of cases (46). Well
circumscribed masses are rarely seen in lobular tumors,
manifesting in as little as 2% to 12% (37). When comparing
the sensitivity of US to mammography, it would appear that the
former is a more valuable imaging tool in the detection of ILC.
Porter et al. (47) investigated the use of mammography and US
in ILC, reviewing 361 cases diagnosed between 1995 and 2010.
This study found that false-negatives occurred in 29.9% of cases
when using mammography, while US had a reported sensitivity
of 97.8% in detecting ILC associated abnormalities. Butler et al.
(48) also evaluated the use of US in cases of ILC. A total of 208
cases were reviewed and of these 81 tumors were considered
invisible on mammography or mammographically subtle.
Results showed that 73.3% of cases that were considered
mammographically invisible were identified by US. Similarly,
91.2% of tumors that were “mammographically subtle” were
visualized using US. Thus, US is a helpful adjunct in the
diagnostic pathway, particularly when faced with a suspicious
physical exam and reportedly normal mammogram (37). The
use of US has proved valuable in significantly improving the
detection of ILC (44).
Magnetic Resonance Imaging
MRI is mostly used in the screening of high-risk BCs, to evaluate
and compare mammographic and US findings, assess
chemotherapy response and to evaluate ipsilateral andJanuary 2021 | Volume 10 | Article 591399
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90% in the detection of BC and a sensitivity of 93% in detecting
ILC (37). This high level of sensitivity is based on the increased
levels of neovascularization in tumors as they constantly create
new blood vessels in a bid to provide nutrients for further tumor
growth. This results in a rapid uptake of gadolinium-based
contrast, which can accumulate in the BC stroma (49). This
high sensitivity also extends to the increased detection of
multifocal, multi-centric and contralateral disease (50). MRI
detects additional tumor foci and contralateral breast disease in
between 16% and 58% of patients with ILC, not detected on
initial mammogram (2). Rodenko et al. (51) compared MRI and
mammographic imaging in the management of ILC in 20
patients, demonstrating an agreement of 85% between
pathology and MRI on tumor size and location. Conversely,
the disease extent shown by mammography correlated with
pathology in 32% of cases. This suggests that MRI is
significantly more accurate than mammography in assessing
disease extent in patients with ILC. MRI could be particularlyFrontiers in Oncology | www.frontiersin.org 7valuable in newly diagnosed ILC to accurately assess disease
extent, which may aid in pre-operative planning (37). A study by
Bedrosian et al. (52) of 267 BC patients concluded that ILC
patients were twice as likely to have their treatment regimen
changed as a result of MRI than patients of any other histological
subtype (2). Despite its high level of sensitivity in the early
detection of BC, a considerable limitation of MRI is the lack of
specificity (53). A low specificity can result in the over-treatment
of patients resulting in extensive surgery with no added clinical
benefit (50). Despite this, the presumed improvement of surgical
outcomes and overall DFS as a result of MRI has been
controversial. A retrospective study by Mann et al. (54)
assessed the impact of MRI on re-excision rates in ILC and
concluded that patients who had an MRI prior to surgery had
significantly lower rates of re-excision (9%) than those who did
not undergo an MRI (27%). This study also reported that MRI
assessment did not result in a higher number of mastectomies
being performed. On the other hand, more recently, a meta-
analysis of pre-operative MRI on surgical outcomes reported thatA B
DC
FIGURE 5 | A case of extensive ILC in a 50-year-old female attending for 1st breast screening. (A) Mammogram: Right and left MLO views. (B) Mammogram is
reported as M3. There is a 5-mm area of concern on the left which is circled. The calcifications are considered benign. The patient does not feel a palpable mass.
(C) An US of the left breast is performed and shows a small 8mm focus close to the nipple. (D) MRI breast follows and this shows an extensive area measuring
approximately 50 mm × 50 mm (circled). Biopsies were performed and showed Gr2 ILC ER8 PgR8 HER negative. Patient had mastectomy and sentinel node biopsy
(SNB) that showed 52-mm Gr2 ILC ER8 PgR8 HER2 negative SNB 0/3. (A) Mammogram: Right and left MLO views (B) Mammogram M3: possibly a 5-mm area of
concern on the left (circled). Calcifications look benign. (C) Ultrasound: One small focus closer to nipple maybe 8mm. (D) MRI: Extensive central disease over
50 mm × 50 mm (circled).January 2021 | Volume 10 | Article 591399
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subtypes and found weak evidence to support the claim that MRI
can reduce re-excision rates in patients with ILC (55). Therefore,
it cannot be claimed with confidence that the use of MRI reduces
the rate of recurrence or DFS in ILC (37). Overall, MRI is
particularly advantageous over standard imaging methods due to
its increased sensitivity in detecting ILC tumors and improving
the detection of ipsilateral and contralateral tumors (Figure 5).
In conclusion, despite its limitations, MRI provides additional
diagnostic information that may be missed during standard
imaging and should be used in combination with US and
mammography in accurately assessing patients with ILC (37, 50).MANAGEMENT AND TREATMENT OF ILC
Treatment protocols for ILC are in line with those used in all other
subtypes of BC. However, features specific to the ILC subtype can
impact both surgical and therapeutic management (3). A typical BC
treatment plan involves a multidisciplinary approach comprising
surgery, radiotherapy and systemic therapies.
Surgical Management of ILC
The decision to proceed with surgery is usually determined on the
basis of TNM stage at presentation, regardless of histology. Cancers
that are deemed operable will usually be managed surgically upfront
while some cancers may require neo-adjuvant therapy (NAC) to
reduce tumor burden and facilitate surgical intervention. In the
majority of cases, breast-conserving surgery in the form of a wide
local excision can be performed, removing the tumor from
surrounding healthy tissue, with clear surgical margins while
maintaining the natural shape of the breast. However, it has been
reported that in up to 65% of ILC cases, a second surgery will be
required (3). ILC is characterized by a higher incidence of diffuse
and multifocal lesions that are hard to detect both on imaging and
intra-operatively, often resulting in re-excision or mastectomy
following original breast-conserving surgery (56). In addition,
axillary lymph node status is a crucial factor in BC prognosis
and influences surgical planning. Sentinel node biopsy (SNB) is
the standard method of assessing the axilla (57). SNB is used in
patients with ILC however the ability to find metastatic deposits is
challenging due to the discohesive nature of the cells (5). Axillary
lymph node metastasis is an important predictor of patient
survival, as the number of metastases increases, patient survival
decreases. However, despite being typically diagnosed at a more
advanced stage, ILC is not thought to be associated with an
increased risk of lymph node metastasis (58). In the case of
nodal involvement, an axillary node clearance should be
performed. This is essential for prognostic purposes and ensures
the lowest rate of axillary recurrence (59). Some studies have
reported that the risk of local recurrence is greater in ILC patients
however the data on local recurrence rates is dependent upon the
duration of follow-up and few studies have specifically focused on
ILC (3). A study by Vo et al. (60) evaluated treatment outcomes
for breast conservation therapy in those with ILC and IDC. The 5-
and 10-year recurrence rates for the ILC group were 1% and 7%
compared to 4% and 9% for the ductal group, respectively. ThisFrontiers in Oncology | www.frontiersin.org 8suggests that breast-conserving surgery leads to similar outcomes
despite tumor histology. Positive surgical margins are one of the
most important factors in determining the risk of local recurrence.
Chagpar et al. (61) reported that patients with a ILC had a greater
likelihood of positive margins following a lumpectomy. Patients
with ILC had positive margins in 15.8% of cases, compared to
9.8% of cases with IDC. This is likely due to the challenges in
accurately assessing disease extent in ILC. A more recent study
exploring the success of re-excision of positive margins in women
with ILC reported that while initial positive margins occurred in
37.6% of cases, clear margins were achieved in 74.2% of patients
who underwent a re-excision lumpectomy (62). This suggests
improvements in the surgical management of ILC, and that
completion mastectomies may not be required in patients who
have positive margins following their initial breast-conserving
surgery. In further support of breast-conserving surgery for ILC,
Fodor et al. (63) concluded that BCSS was not affected by surgical
treatment (breast-conserving surgery or mastectomy) in patients
with ILC, spanning a 15-year period. Overall, this suggests that
breast-conserving surgery can be safely implemented in the
surgical management of ILC without compromising long-term
clinical outcomes.
Chemotherapy in ILC
In addition to surgery, systemic treatment to manage ILC is also
essential. NAC is widely used in the treatment of BC in order to
relieve tumor burden, allowing breast-conserving surgery to be
facilitated. Specific benefits of NAC include the ability to monitor
tumor response in vivo, predict outcome and adjust treatment
regime as necessary (64). The typical outcome measurement of
NAC is the achievement of pathological complete response
(pCR) as this is a strong early surrogate marker for OS in BC.
However, the overall consensus is that ILC responds poorly to
chemotherapy with lower OS rates following NAC than observed
in IDC (3, 65). This is in part due to pCR occurring less
frequently in ILC subset (2). Cocquyt et al. (66) looked at the
clinical response and pCR rates between IDC and ILC in 135
patients with BC. They found that the overall response for IDC
was 75% compared to 50% for ILC (P = 0.0151). pCR was
reported as 15% in patients with IDC and 0% in those with ILC.
The type of chemotherapy used was found not to affect this.
In addition, Lips et al. (67) performed an analysis of a large
dataset comprising two NAC trials, 676 patients in total, of
which 75 were of ILC. pCR rates were compared between IDC
and ILC and showed that following NAC, ILCs were significantly
less likely to achieve pCR than IDCs (11% versus 25%). The
CTNeoBC meta-analysis by Cortazar et al. (68) reported that
while there is a significant association between pCR and OS in
BC, long-term outcomes are influenced by BC subtypes. Patients
with triple-negative BC and those with HER2-positive, hormone-
receptor negative tumors were found to have the strongest
association between pCR and long-term outcomes. Suggesting
that pCR may not be prognostic of long-term outcome in
patients with ILC.
The poor chemo-sensitivity of ILC can likely be explained by
its hallmark biological characteristics and the expression of
specific markers. Namely, low histological grade, ER positivity,January 2021 | Volume 10 | Article 591399
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assessed with Ki-67 immunohistochemistry (5). Given the poor
response rate to NAC, residual tumor volumes are a major
challenge in ILC due to the greater risk of local recurrence.
The inability of NAC to adequately downstage and reduce tumor
burden in ILC has resulted in lower rates of breast-conserving
surgery and higher rates of conversion to rescue mastectomy due
to positive margins (69). If NAC is unlikely to improve rates of
breast-conserving surgery in ILC then it’s use should be carefully
considered given the potential life-threatening toxicities (4).
Interestingly, despite responding poorly to chemotherapy, ILC
patients do not have increased rates of recurrence and survival is
comparable to IDC (68, 69). Many molecular tests are now
available to better inform treatment decisions, which may help to
avoid treating ILC patients inappropriately. An example of this is
the Oncotype DX 21-gene clinical assay. A study by Thomas
et al. (70) compared survival outcomes between ET and
chemoendocrine therapy in patients with ILC, utilizing
Oncotype Dx. The use of chemotherapy in addition to ET did
not improve survival outcomes for patients with ILC compared
to ET alone. Oncotype Dx testing in ILC patients also revealed
most cases would receive little benefit from chemotherapy, in line
with the survival outcomes observed. There remains little in the
literature focusing on the role of Oncotype DX in the
management of ILC, with more research this may prove a vital
tool in impacting ILC treatment decisions regarding the use of
chemotherapy (71).
Endocrine Therapy in ILC
As most ILCs are strongly hormone receptor positive, treatment
decisions are often in favor of endocrine-based therapy, to which
a vast number of patients exhibit a good response (4, 13). Most
studies have shown ET to be more beneficial when used in the
adjuvant setting, particularly in post-menopausal women, due to
its high correlation with reducing risk of recurrence. Yet, in the
neo-adjuvant setting, ET may be warranted in order to
downstage tumors, and potentially allow breast-conserving
surgery (72). Classically, tamoxifen, a selective ER modulator is
indicated for pre-menopausal women while an aromatase
inhibitor such as letrozole or anastrozole is recommended for
post-menopausal women. However, research suggests that in the
case of ILC, not all endocrine therapies are of equal value.
Metzger Filho et al. analyzed the effectiveness of adjuvant
letrozole compared with tamoxifen in cases of patients with
ILC and IDC, as part of the BIG 1-98 trial (6). Overall patients
with ILC had a greater benefit from treatment with letrozole than
with tamoxifen. Across the 8-year follow up period, DFS was
reported at 66% for tamoxifen compared to 82% for letrozole
treated ILC.While OS was 74% with tamoxifen compared to 89%
with letrozole (5). These results recommend the use of an
aromatase inhibitor as the treatment of choice in women with
ILC and suggest the possibility of endocrine resistance with
tamoxifen treatment (6). However, it is inevitable that a large
number of patients will eventually become resistant to treatment
regardless of the endocrine agent (73). The mechanistic drivers
of endocrine resistance in ILC are as yet undefined but may beFrontiers in Oncology | www.frontiersin.org 9explained by tumor profiling. Tumors acquiring mutations in
ESR1, ERBB2 and FGFR1 have been found to exhibit a poorer
response to targeted ET (73). Sikora et al. (74) used an ER
positive ILC cell line (MDA-MB-134VI) to analyze this altered
response to tamoxifen. The study showed that the ER drives gene
expression in ILC cells that promotes cell growth in the presence
of tamoxifen. Additionally, FGFR1 signaling was vital in
maintaining cell viability and therefore FGFR1 inhibition may
provide a target for reversing tamoxifen resistance (5).
Endocrine treatment as a neo-adjuvant approach is less well
documented however the few studies conducted suggest this may be
preferable to chemotherapy (4). A retrospective study by Dixon
et al. (75) of 61 ILC patients reported a 66% reduction in tumor
volume following three months of neo-adjuvant letrozole and a
successful breast conservation rate of 81%. This small study
demonstrates the potential to increase the rate of breast
conservation and in turn reduce mastectomy rates among women
with ILC. ET may be further enhanced when used in conjunction
with targeted therapies. Cyclin-dependent kinases (CDK) 4/6
inhibitors such as palbociclib, ribociclib and abemaciclib are
currently licensed for use in advanced BCs that are ER positive
and HER2 negative in combination with conventional ET. The role
of CDK4/6 inhibitors in combination with ET was also explored
both in the adjuvant and neoadjuvant settings. To our knowledge,
four clinical trials have been published to date. NeoPalAna, a phase
II trial that evaluated anastrozole monotherapy versus anastrozole
plus palbociclib in ER+ HER2-ve BC patients (76), PALLET, a
phase II trial which compared letrozole monotherapy versus
letrozole plus palbociclib administered in different schedules (77),
neoMONARCH, a phase II trial in which patients were randomized
to receive either anastrozole monotherapy, abemaciclib
monotherapy or their combination (78) and MONALEESA-1,
phase II that compared letrozole monotherapy versus letrozole
plus ribociclib in two different doses 400 and 600 mg (79).
Despite the fact that none of these trials resulted in improved
clinical outcomes, preliminary results have showed some analogies
even though the study design, primary endpoints and number of
patients differ from study to study. For example, the rate of Ki67
response and complete cell cycle arrest seemed to be higher in the
combination arm compared to ET alone. Whether the better anti-
proliferative effect of the CDK4/6 inhibitors plus ET translates into a
better clinical outcome is still debatable.
Finally, PELOPS trial (Clinical Trial registration no.
NCT02764541) is currently evaluating the use of neo-adjuvant
palbociclib in combination with ET (letrozole or tamoxifen) in
hormone receptor positive BC. Moreover, this trial will compare
the effectiveness of letrozole versus tamoxifen in cohorts of
patients with ILC, through measurement of the anti-
proliferative activity. Therefore, this may prove vital in guiding
and informing the future endocrine treatment of ILC.
At the last ESMO congress (2020), the results of two
randomized phase III studies investigating the efficacy of
CDK4/6 inhibitors in addition to standard adjuvant ET in
high-risk early BC patients have been presented. In particular,
MonarchE trial reported a significant advantage of 3.5% in term
of invasive DFS in patients who received abemaciclib plus ETJanuary 2021 | Volume 10 | Article 591399
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(80). Conversely, in the PALLAS trial, the addition of palbociclib
to adjuvant ET did not prolong invasive DFS versus ET alone
(88.2% versus 88.5%) (81). These conflicting results may be due
to several differences between the two trials such as study
populations (more high-risk patients enrolled in MonarchE
trial), drug exposure and follow up duration. However, none of
the two studies provided a subgroup analysis for patients with
ILC. Key characteristics of ILC are summarized in Table 2.FUTURE DIRECTIONS IN ILC
Improvements in understanding the distinct molecular profile of
ILC are essential to facilitate the development of effective future
treatments. Despite ILC responding well to ET, endocrine
resistance is a challenge that must be overcome. This has led to
ER transcriptional regulators such as FOXA1 and RUNX1
becoming potential targets of further research into endocrine
resistance in ILC (30). In addition, the PI3K pathway may also
hold the key to unlocking endocrine resistance, as mutations
within this pathway occur with an increased frequency in ILC
(35). In the SOLAR-1 phase III clinical trial, addition of PI3K
inhibitor, alpelisib, to fulvestrant was able to prolong
progression-free survival (PFS) in patients with PIK3CA-
mutated, hormone receptor positive, HER2-negative BC
compared to fulvestrant alone (82). Another promising area of
research focusing on ILC is the use of crizotinib combined with
fulvestrant. The phase II trial, known as the ROLO study
(Clinical Trials registration no. NCT03620643) will determine
the effectiveness of combination crizotinib and fulvestrant in
shrinking E-cadherin deficient, ER-positive lobular BC and
diffuse gastric cancer. Crizotinib targets alterations in the
CDH1 gene that cause E-cadherin deficiency and inhibits
tyrosine kinase ROS1, which is vital for cell viability, while
fulvestrant blocks the ER signaling pathway on BC cells.
Crizotinib is already licensed in the treatment of non-small cellFrontiers in Oncology | www.frontiersin.org 10lung cancer and, if found to be effective in the treatment of ILC,
may result in further trials investigating the inhibition of ROS1
as a novel therapeutic strategy for ILC (83). FGFR signaling is
essential to the survival of cancer cells, thus targeting aspects of
this pathway may provide new therapeutic options in treating
ILC. Amplifications of FGFR1 are the most common reported
alterations occurring in around 14% of BCs (84, 85). Reis-Filho
et al. (86) performed a comprehensive molecular analysis of
13 cases of ILC. Comparative genomic hybridization identified
amplifications of 8p12-p11.2 driven by FGFR1. Using the cell
line MDA-MD-134, FGFR1 expression could be inhibited
through the use of small interfering RNA or a small-molecule
chemical inhibitor. Overall, these data suggest that FGFR1
inhibitors may prove useful as a therapeutic in ILC. In a recent
study by Hayley et al. (87) RNA sequencing of primary ILC
samples revealed high expression of bromodomain protein 3
(BRD3). This was associated with poor recurrence-free survival.
To further investigate this, ILC cell lines were tested with JQ1, a
known potent inhibitor of bromodomain proteins. JQ1 was
able to inhibit cell growth in the ILC cell lines, however some
of the cells were resistant to JQ1-induced apoptosis. Following
further molecular analysis, JQ1 resistant cell lines were found to
express high levels of FGFR1-4. Combining JQ1 with an FGFR1
inhibitor resulted in cell death in the original JQ1 resistant cells.
Therefore, the inhibition of BRD3 could represent a novel
therapeutic target.
Novel therapeutic approaches such as immunotherapy are
becoming more promising in the treatment of BC, particularly in
triple negative cancers. However, the immune response in ILC is
less well studied (88). The presence of tumor infiltrating
lymphocytes has been found to correlate with a good prognosis
with typically higher rates of pCR after chemotherapy. Desmedt
et al. (89) recently evaluated the prevalence, levels and
composition of tumor infiltrating lymphocyte and their
association with clinico-pathological outcomes in ILC. The
results concluded that levels of tumor infiltrating lymphocytes
were significantly lower in ILC compared with IDC. Although,
higher levels of lymphocytes were associated with young age,
nodal involvement and high proliferation suggesting high
lymphocyte infiltration is associated with a worse prognosis in
ILC. This suggests that immune infiltration may play a different
role in ILC compared with IDC.
Du et al. (88) recently reported that ILC exhibited a higher
activity of almost all types of immune cells compared to IDC.
This suggests that ILC may demonstrate a greater sensitivity to
existing immune check-point inhibitors. The use of immune
check-point inhibitors is the current focus of a phase II trial
known as the GELATO study (Clinical Trials registration no.
NCT03147040). This trial aims to assess the efficacy of
combining chemotherapeutic agent carboplatin with
monoclonal antibody atezolizumab in patients with metastatic
ILC (90). Atezolizumab works by targeting PDL-1, an inhibitory
factor that can limit the development of the T-cell response. By
blocking the effects of PDL-1, atezolizumab can reduce this
immunosuppressive signal and increase the body’s immune
response against ILC tumor cells.TABLE 2 | Summary of Key Characteristics of ILC.
Feature Details
Epidemiology • Post-menopausal women
• Caucasian western populations have the highest rates
Incidence • Increasing incidence over past two decades
• 10%–15% all invasive breast cancer
• Most common subtype after IDC of no special type
Clinical
Presentation
• Often vague symptoms
• Ill-defined mass
• Tumor may be impalpable
Radiology • Mammography has a low sensitivity
• Ultrasound can improve detection of mammographically
invisible tumors
• MRI valuable adjunct to assess disease extent
Treatment • Challenging to achieve surgical excision with clear margins
due to the diffuse nature of the disease
• Generally poor response to chemotherapy
• Excellent response to endocrine therapy, however managing
resistance is still a major challengeJanuary 2021 | Volume 10 | Article 591399
Wilson et al. Lobular Breast CancerCONCLUSION
ILC represents a biologically distinct subset of BC, characterized
by hallmark molecular features such as loss of E-cadherin
expression, ER positivity, and HER2 negativity. This unique
biology directly affects initial presentation and makes early
diagnosis challenging, and decisions regarding both surgical
and systemic therapy are ultimately more difficult compared
with other BC subtypes. Given that the biological characteristics
of ILC are considered favorable, an excellent prognosis should be
expected over other invasive BCs. To improve outcomes of
patients with ILC more emphasis should be placed on early
detection and imaging techniques to accurately evaluate disease
extent given the increased propensity for multifocal and
contralateral disease. Evidence highlighting the value of MRI
for detection and diagnosis of ILC is emerging. More accurate
imaging methods will better inform surgical decisions and may
lead to an increase toward the number of breast-conversing
surgeries performed and a reduction in the incidence of positive
margins and subsequent rescue mastectomies. Despite these
challenges, key features such as ER and PR positivity are
associated with an excellent response to ET among ILC
patients. Evidence suggests that the use of an aromatase
inhibitor such as letrozole should be the treatment of choice in
ILC due to the inevitable endocrine resistance associated with
tamoxifen. In the case of advanced BC, the use of targeted
therapies such as CDK4/6 inhibitors in combination with
traditional ET is warranted. This is currently being investigatedFrontiers in Oncology | www.frontiersin.org 11in the neo-adjuvant setting in the PELOPS clinical trial. It is
evident that mutations within the CDH1 gene are common
factors in the pathogenesis of ILC alongside mutations within
the PI3K pathway. Therefore, therapies targeting these pathways
represent an attractive option in ILC patients. Furthering our
understanding of the unique biology of ILC is essential to
facilitate the development of novel therapeutic strategies,
moving toward precision medicine for patients diagnosed with
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